# Alembic Pharma gets USFDA nod for generic constipation drug

2026-08-07T22:49:49+00:00 | Business & Economy | Indian Opinion Desk

Corroboration: 1 independent outlet

Alembic Pharmaceuticals has received final USFDA approval for its generic Prucalopride Tablets, used to treat chronic idiopathic constipation in adults. The drug is therapeutically equivalent to Takeda's Motegrity. Based on IQVIA data, Alembic estimates the US market for the drug was $100 million in the year ending March 2026.

## Coverage

- thehindu.com <https://www.thehindu.com/business/Industry/alembic-pharma-gets-us-fda-nod-for-generic-chronic-constipation-drug/article71277708.ece>

Tags: Alembic Pharma, chronic constipation, generic drugs, Motegrity, pharma exports, USFDA
Canonical: https://indianopinion.org/alembic-pharma-gets-usfda-nod-for-generic-constipation-drug/
License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources.
Cite: https://indianopinion.org/alembic-pharma-gets-usfda-nod-for-generic-constipation-drug/#story-in-brief

Review state: restored archive article, accurate at time of publication, not offered to search indexes.